Please assess the completion status of the following clinical trial:

Trial Title: Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:• Informed consent~* Age \> 18 years~* Performance status 0-1; expected survival ≥ 3 months~* Patient with histologically or cytologically confirmed locally advanced or metastatic adenocarcinoma of the breast~* Liver metastases not suitable for local treatment~* Extrahepatic disease should be determined by PET-CT-scan.~* No progression on treatment with capecitabine.~* Prior treatment with taxane (adjuvant or for metastatic disease)~* Metastases \< 70 % of the liver~* Neutrophile granulocytes \> 1.5 x 109/l og thrombocytes \> 100 x 109/l~* Bilirubin \< 2.0 x UNL (upper normal limit).~* Creatinine-clearance \> 30 ml/min.~* INR \< 1.6.~* If the patient is HER2-positive:Baseline LVEF ≥ 50 %~Exclusion Criteria:~* History of chemotherapy within the 4-week period prior to the start of trial medication~* Other current or prior malignant disease except adequately treated and cured carcinoma in situ of the cervix or squamous cell carcinoma of the skin.~* Previous treatment with oxaliplatin~* Cytotoxic or experimental treatment within a 14 days period before start of trial medication~* The patient is not allowed to participate in other clinical trials.~* Any clinical symptoms suggesting peripheral neuropathy \< or equal to grade 2 or CNS metastases (In case of clinical suspicion on CNS metastases a MR or CT scan should be performed within 4 weeks before inclusion~* Other severe medical conditions e.g. severe cardial disease or AMI \< 1 year~* Presence of diseases which prevent oral therapy.~* Patients with uncontrolled infection~* Pregnant or lactating women~* Women capable of childbearing not using a sufficient non-hormonal method of birth control~* Patients not able to understand the treatment or to collaborate.~* Prior serious or unsuspected reaction after treatment with fluoropyrimidine~* Known prior hypersensitivity reactions to the agents~If the patient is HER2-positive:~* Dyspnoea in due to complication related to malignant disease e.g.lung metastases with lymphangitis or other conditions with need of supportive oxygen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).